Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Affiliations

• ¹ Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
• ² Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
• ³ Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
• ⁴ Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Melbourne, Victoria, Australia.
• ⁵ Department of Microbiology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
• ⁶ Victorian Infectious Disease Reference Laboratory (VIDRL), The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
• ⁷ Infectious Diseases, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
• ⁸ Department of Infectious Diseases, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
• ⁹ Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo, Hokkaido, Japan.
• ¹⁰ Department of Gastroenterology, The Royal Melbourne Hospital, Parkville, Victoria, Australia [email protected].
• ¹¹ Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.